/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained drug delivery moving toward clinical use

    Ophthalmologists have terrific treatments for glaucoma and less-than-terrific treatment results. Eye-drop adherence falls below 50% within a few months. One solution: replace daily drops with sustained-delivery technology.

    “We have a spectrum of drug-delivery technologies that are moving quickly toward clinical relevance,” said Eliot Lazar, MD, president of elCON Medical. “These new technologies will help us support and treat glaucoma patients better than we have ever been able to do with topical medications.”

    Dr. Lazar co-moderated the “New Horizons in Glaucoma Drug Delivery” session that reviewed nine development programs. Some companies are focusing on micro- and nano-scale particles, others on gels and solid drug depots. Some are designed for topical administration, some for injection, and others are implanted like a contact lens. All aim for controlled, steady state delivery over specific time periods to enhance drug delivery to the target tissue and improve therapeutic outcomes.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results